Navigation Links
New Evidence Points to a "Profits Over Efficacy" Approach to Drug Testing
Date:2/15/2012

SACRAMENTO, California, February 15, 2012 /PRNewswire/ --

It has become common for people with chronic pain who use opioid pain medication to be required to submit to random drug screens as a condition of treatment.  The rationale for the use of this billable procedure is to prevent and reduce opioid associated morbidity and mortality.  However, there remains insufficient evidence as to the efficacy of drug testing people with chronic pain.      

A new article entitled "Profit-Driven Drug Testing" published today in the Journal of Pain & Palliative Care Pharmacotherapy suggests that drug testing may have also been motivated by money.

"The paper takes a retrospective look at drug testing and presents Medicare data which shows a meteoric climb in drug screens," explains report author Mark Collen, a patient advocate.  "I was very surprised when I saw the numbers, which shows that between 2000 and 2009 the number of all Medicare laboratory services increased by about 48%, while the number of drug tests conducted in physicians' offices increased over 3,000,000%."  

The article provides evidence which suggests doctors made as much as $200 per screen and that Medicare identified and closed the drug testing profit center.  In addition, the paper looks at clinical laboratories whose primary business is to provide toxicology screens for people on opioid therapy and their alleged kickbacks to physicians.

Mark Collen is one of a few in the literature to question the use of drug screens for people with chronic pain.  In 2009, Collen wrote an article published in The Journal of Law, Medicine & Ethics entitled "Opioid Contracts and Random Drug Testing for People with Chronic Pain - Think Twice."  A second article followed in 2011 entitled "The Fourth Amendment and Random Drug Testing of People with Chronic Pain" published in the Journal of Pain & Palliative Care Pharmacotherapy.  While interviewing a physician for a possible third article, Mr. Collen was told that doctors would likely conduct fewer drug screens as a result of Medicare having changed their reimbursement rules.  

"He explained to me that physicians were charging Medicare around $225 per test but now could only bill them at $20, and that doctors would have less incentive to drug test their pain patients," says Collen.

Collen began to search for evidence to support or refute these claims and the results are published in the Commentary article. "The lesson remains the same," Collen says, "profit-driven healthcare will always be inferior to evidence-based medicine."  

According to the Institute of Medicine, chronic pain affects 116 million American adults and costs the US economy approximately $600 billion per year. Mark Collen is a patient advocate and founder of PainExhibit.com.  His focus is on improving pain care and reducing the healthcare costs associated with chronic pain.

The Journal of Pain & Palliative Care Pharmacotherapy is published by Informa Healthcare.  


'/>"/>
SOURCE Journal of Pain & Palliative Care Pharmacotherapy
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. GiiResearch.com: Computed Tomography (CT) Systems - Technological Advances and Positive Clinical Trial Evidences to Drive the Market
2. New FREEDOM Data Adds to Compelling Evidence in Support of More Frequent Home Hemodialysis with NxStage System One
3. Pearl Therapeutics Presents New Scientific Evidence Supporting Versatility of Its Novel Cosuspension MDI Platform
4. "Off-Label" Use of Antipsychotic Drugs for Some Conditions Not Supported By Evidence
5. NxStage: NIH Study Published in New England Journal of Medicine Adds to Growing Body of Evidence in Support of More Frequent Hemodialysis
6. Newly-Published Colchicine Safety Data Provide First Evidence-Based Dosing Guidance to Avoid Potentially Serious Interactions With Commonly Prescribed Drugs
7. Elsevier CPM Resource Center to Integrate Evidence-Based Clinical Content Software at Providence Health & Services
8. AVAC Says Results of New PrEP Trials Provide Clear Evidence that Antiretroviral Drugs for Prevention Can Help End the AIDS Epidemic; Calls for Quick Action to Move Landmark HIV Prevention Results Toward Lifesaving Programs
9. Medco, United BioSource and Sanofi Signed Global Agreement to Improve Quality of Patient Care Through Real-World Evidence
10. Approved Biologic Therapies in Rheumatoid Arthritis Show Further Evidence of Efficacy and Reduction in Joint Damage at the 2011 European League Against Rheumatisms Congress
11. Latest Clinical Evidence Supports Promising Outlook for Low-Dose Molecular Breast Imaging (MBI)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... Following receiving CE Marking in Europe ... AMAR is a major milestone for the country where the device was developed ... market in Israel   ... inclusion in the National Health Basket , Israel , ... E-QURE Corp. (OTCQB: EQUR), a leader in medical devices for the treatment of advanced wound ...
(Date:2/24/2017)... Research and Markets has announced the addition of the ... their offering. ... research Dry eye Drugs Price Analysis and Strategies - 2016, provides drug ... research answers the following questions: What are ... are they positioned in the Global Dry eye market? ...
(Date:2/24/2017)... Feb. 23, 2017 The U.S. Food ... PhenoTest BC Kit, performed on the Pheno System. ... that cause bloodstream infections and provide information about ... to (antibiotic sensitivity). The test also reduces the ... important information, which can guide antibiotic treatment recommendations ...
Breaking Medicine Technology:
(Date:2/24/2017)... , ... February 24, 2017 , ... The Smart Machine ... from Oxford University predict that 47 percent of all jobs in the United States ... “smart” and “successful.” The day of the aggressive know-it-all who steamrolls over colleagues is ...
(Date:2/24/2017)... ... February 24, 2017 , ... With ProGlass Prism users now ... . Users have total control over position, rotation, distortion, edge softness, edge blur, chromatic ... Cut Pro X. , With ProGlass Prism users are given the tools and ...
(Date:2/24/2017)... Farifax, VA (PRWEB) , ... February 24, 2017 , ... ... winners for excellence in radiology marketing programs at the annual Building Better ... the Worthington Renaissance Fort Worth Hotel in Fort Worth, Texas. Nine awards are given ...
(Date:2/23/2017)... MA (PRWEB) , ... February 23, 2017 , ... ... and Department of Justice jointly issued a letter to withdraw previous ... accordance with their gender identity. The guidance issued in May 2016 by the ...
(Date:2/23/2017)... ... 2017 , ... Los Angeles-based weight loss surgeon Michael Feiz, M.D., F.AC.S. will ... to Hot,” which will begin airing on February 24, 2017. The show chronicles the ... 2012 reality television series, “Here Comes Honey Boo Boo.” The earlier series from TLC ...
Breaking Medicine News(10 mins):